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[90Y-DOTA]-TOC in neuroendocrine tumors:
long-term outcome of a phase I dose escalation study
Nicolas Marincek1†, Ann-Catherine Jörg1†, Philippe Brunner1, Christian Schindler2, Michael T Koller3,
Christoph Rochlitz4, Jan Müller-Brand1, Helmut R Maecke5, Matthias Briel3,6 and Martin A Walter1,7*Abstract
Background: We describe the long-term outcome after clinical introduction and dose escalation of somatostatin
receptor targeted therapy with [90Y-DOTA]-TOC in patients with metastasized neuroendocrine tumors.
Methods: In a clinical phase I dose escalation study we treated patients with increasing [90Y-DOTA]-TOC activities.
Multivariable Cox regression and competing risk regression were used to compare efficacy and toxicities of the different
dosage protocols.
Results: Overall, 359 patients were recruited; 60 patients were enrolled for low dose (median: 2.4 GBq/cycle, range 0.9-
7.8 GBq/cycle), 77 patients were enrolled for intermediate dose (median: 3.3 GBq/cycle, range: 2.0-7.4 GBq/cycle) and 222
patients were enrolled for high dose (median: 6.7 GBq/cycle, range: 3.7-8.1 GBq/cycle) [90Y-DOTA]-TOC treatment. The
incidences of hematotoxicities grade 1–4 were 65.0%, 64.9% and 74.8%; the incidences of grade 4/5 kidney toxicities were
8.4%, 6.5% and 14.0%, and the median survival was 39 (range: 1–158) months, 34 (range: 1–118) months and 29 (range:
1–113) months. The high dose protocol was associated with an increased risk of kidney toxicity (Hazard Ratio: 3.12 (1.13-
8.59) vs. intermediate dose, p = 0.03) and a shorter overall survival (Hazard Ratio: 2.50 (1.08-5.79) vs. low dose, p = 0.03).
Conclusions: Increasing [90Y-DOTA]-TOC activities may be associated with increasing hematological toxicities. The dose
related hematotoxicity profile of [90Y-DOTA]-TOC could facilitate tailoring [90Y-DOTA]-TOC in patients with preexisting
hematotoxicities. The results of the long-term outcome suggest that fractionated [90Y-DOTA]-TOC treatment might allow
to reduce renal toxicity and to improve overall survival.
Trial registration: ClinicalTrials.gov number: NCT00978211
Keywords: Radiopeptide therapy, DOTATOC, DOTA-TOC, Survival, Neuroendocrine tumorBackground
Neuroendocrine tumors comprise a spectrum of different
malignancies with a yearly increasing incidence and preva-
lence [1]. Most of these tumors express subtypes of the
somatostatin receptor [2], which permits binding and in-
ternalization of the natural ligand, the 14 amino acid pep-
tide somatostatin (Figure 1A). Stepwise modifications of
the somatostatin sequence led to the development of the* Correspondence: m.a.walter@gmx.net
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reproduction in any medium, provided the orbiologically more stable 8 amino acid somatostatin
analogue Octreotide [3,4] (OC, Figure 1B), which nowadays
has become a valuable tool for the treatment of symptom-
atic neuroendocrine tumors [5,6].
Introduction of a tyrosine into the third position of the
Octreotide sequence resulted in Tyr3-Octreotide (TOC,
Figure 1C), which allowed for iodination of the tyrosine
residue with the γ-emitter 123I and subsequent somatostatin
receptor targeted imaging [7]. The success of somatostatin
receptor targeted imaging finally provided the rational for
somatostatin receptor targeted radiotherapy.
For the use in somatostatin receptor targeted radiother-
apy we coupled TOC with the chelator DOTA, which
led to the octapeptide DOTA-TOC [8] (Figure 1D).al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 The natural somatostatin receptor ligand, the 14 amino acid peptide somatostatin (A), was abridged to the biologically more
stable 8 amino acid peptide Octreotide (OC, B), which is used for the treatment of symptomatic neuroendocrine tumors. Introduction
of a tyrosine into the 3rd position of the Octreotide sequence resulted in Tyr3-Octreotide (TOC, C), which allows for iodination of the
tyrosine residue with the γ-emitter 123I and subsequent somatostatin receptor targeted imaging. For the use in somatostatin receptor
targeted radiotherapy TOC was coupled with the chelator DOTA, which led to the study drug, the octapeptide DOTA-TOC (D).
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including the γ-emitter 111In and the β-emitters 177Lu and
90Y. In an in-vivo treatment model [90Y-DOTA]-TOC was
able to completely eliminate somatostatin receptor expres-
sing xenografts [9]. Based on these promising in-vivoresults we introduced [90Y-DOTA]-TOC into the clinic
within a phase I dose escalation study.
The present work reports the long-term outcome of the
dose escalation study with [90Y-DOTA]-TOC in patients
with progressive neuroendocrine tumors.
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Patients
We included patients (i) older than 18 years with (ii) his-
tologically confirmed neuroendocrine tumors, (iii) metas-
tasized disease, (iv) disease progression within 12 months
before study entry and (v) visible tumor uptake in the
pre-therapeutic somatostatin receptor scintigraphy. We
excluded patients with (i) concurrent anti-tumor treat-
ment, (ii) pregnancy, (iii) breast-feeding, (iv) urine incon-
tinence, (v) preexisting hematological toxicities grade 3/4,
and (vi) severe concomitant illness. The study was
designed and carried out in accordance with good clinical
practice guidelines, Swiss drug laws and the Declaration
of Helsinki. The study was approved by the local eth-
ics committee for human studies (EKBB-Reference-No.:
M120/97; www.ekbb.ch) and registered (ClinicalTrials.gov
number NCT00978211). Written informed consent was
obtained from all participants.Treatment
DOTA-TOC was synthesized in a five step synthetic pro-
cedure according to Good Laboratory Practice [8]. Radiola-
beling was performed with the β-emitter 90Y for therapeutic
purpose and 111 MBq of the γ-emitter 111In for intrathera-
peutic imaging [10,11]. Quality control was performed using
solid phase extraction and high performance liquid chroma-
tography, with a minimum required labeling yield >99.5%.
To the best of our knowledge, at the start of patient
recruitment no published report was available on systemic
applications of an 90Y labeled peptide into humans.
Consequently, the activity for the initial application of
[90Y-DOTA]-TOC was based on dosimetric assumptions
as previously described [8]: (i) Based on the biodistribution
of radiolabeled somatostatin analogues in imaging studies
the kidneys were assumed to be the dose limiting organs
for [90Y-DOTA]-TOC application. (ii) Based on dosimetric
studies using a kidney phantom the kidney dose was
assumed to be 1 Gy per 0.148 GBq of [90Y-DOTA]-TOC.
In the first arm (Low Dose Group), patients were treated
with 4 initial cycles of escalating [90Y-DOTA]-TOC activities
from 0.925 to 3.9 GBq, resulting in estimated kidney doses
from 6.25 Gy to 25 Gy, which equals 25% to 100% of the
maximum tolerated kidney dose in external beam irradiation
[12]. As grade 3 hematotoxicities already occurred with this
initial dose protocol and as severe hematotoxicities are po-
tentially life-threatening, the further escalation steps were
performed adapted to the body surface until the occurrence
of grade 4 hematotoxicities. In the second arm (Intermediate
Dose Group), patients were treated with 4 initial cycles of
1.85 GBq/m2 body surface [90Y-DOTA]-TOC, equating the
maximum activities applied in the first arm. Finally, in
the third arm (High Dose Group), the number of
initial cycles was reduced from 4 to 2 using twice the[90Y-DOTA]-TOC activity used in the second arm,
3.7 GBq/m2 body surface.
After these initial cycles, further cycles were per-
formed in case of (i) stabilization or decrease in the sum
of the longest diameters of all pre-therapeutically detected
tumor lesions, (ii) improvement in at least one of the five
key symptoms: flush, diarrhea, pain, fatigue and invol-
untary weight-loss or (iii) post-therapeutic marker de-
crease after pre-therapeutic marker increase, as previously
described [13]. For these further treatment cycles, patients
crossed over to the actual dose escalation step at the time
of re-treatment.
The use of Hartmann HEPA solution containing 10.7 g/L
arginine and 6.9 g/L lysine and later NaCl containing
20.7 g/L arginine and 20.0 g/L lysine was introduced during
the low dose protocol and was then continued during the
intermediate and the high dose protocol. The solutions
were applied before and after [90Y-DOTA]-TOC injection
to inhibit tubular re-absorption of the radiopeptide
[10,13,14]. The intratherapeutic biodistribution of the
radiopeptide was imaged and tumor as well as kidney up-
take were scored using a 4-point scale as previously
described [13,15]: no uptake (score 0), uptake lower than
liver uptake (score 1), uptake similar to liver uptake (score
2) and uptake higher than liver uptake (score 3). Patients
were hospitalized 3 days for each cycle in accordance with
the Swiss requirements for legal radiation protection.
Follow-up
During hospitalization, clinical status and vital signs were
monitored before and for 72 hours following each thera-
peutic application. All toxicities were continuously recorded.
After discharge, blood chemistry and hematologic para-
meters were measured in biweekly intervals for 10 weeks
after each cycle or until normalization of marker levels.
Further cycles were withheld because of progression,
permanent toxicity, loss of the ability to travel to the
treatment center or denial of further treatment. At this
point, the follow-up was performed to obtain informa-
tion on survival and long-term toxicities until the
patient’s death. Follow-up data were obtained from the
referring centers, with a minimum frequency of 2
follow-up visits per year, adapted to the patient’s indi-
vidual requirements. All follow-up data were centrally
collected and each case was reviewed and approved for
completeness at the study center. Family physicians and
the patients were directly contacted if additional follow-
up results were needed.
Acute and long-term adverse events were graded
according to the Common Terminology Criteria for
Adverse Events version 3.0 (http://ctep.cancer.gov/pro-
tocolDevelopment/electronic_applications/docs/ctcaev3.pdf)
of the National Cancer Institute. The kidney function
was assessed using the Modification of Diet in Renal
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classified according to guidelines of the National Kidney
Foundation (www.kidney.org). Severe renal toxicity was
defined as toxicity grade 4 or 5 (glomerular filtration
rate <30 or <15 mL/min/1.73 m2).
Outcomes and Statistical Analyses
The main outcomes for this dose escalation study were
hematological and renal toxicities. Predictors of hema-
tological toxicities were investigated using logistic regres-
sion with the following pre-specified prognostic variables:
gender, age, histology, duration of disease, previous surgery
vs. no surgery, previous chemotherapy vs. no chemother-
apy, previous radiation vs. no radiation, solitary metastases
vs. multiple metastases, liver metastases vs. no liver metas-
tases, bone metastases vs. no bone metastases, tumor up-
take score and applied [90Y-DOTA]-TOC activity.
In order to accurately investigate predictors of renal tox-
icity the competing risk of death prior to renal toxicity
was considered in all analyses. Cumulative incidence func-
tions were used to display the proportion of patients with
renal toxicity or the competing event of death as time pro-
gressed [17] and a Cause-specific Cox regression model for
the subdistribution hazard [18] was employed. The follow-
ing pre-specified variables were tested in the model: gen-
der, age, baseline glomerular filtration rate, cumulative
applied [90Y-DOTA]-TOC activity and treatment with low
or high vs. intermediate doses of [90Y-DOTA]-TOC. Sur-
vival was not an a priori study endpoint; however, in a
post hoc analysis we also analyzed the survival in the three
groups from time of first [90Y-DOTA]-TOC treatment to
death from any cause.
Predictors of survival were studied by multivariable
Cox regression with the pre-specified candidate variables
used for analyses of all hematotoxicities as described
above, adjusted to the cumulative applied [90Y-DOTA]-
TOC activity.
Sensitivity analyses were performed to assess the influ-
ence of the year of treatment and the influence of all
pre-specified predictors on the 1-, 2- and 5-years sur-
vival, respectively. Two-sided p values of <0.05 were
considered to indicate statistical significance.
Results
Patients
A total of 563 patients were screened for eligibility, 68
patients (12.1%) were not eligible, 130 patients (23.1%)
were eligible but not treated with [90Y-DOTA]-TOC. The
last 6 patients (1.1%) of the intermediate dose protocol
had received 2 cycles according to the intermediate dose
protocol and then 2 cycles according to the high dose
protocol; due to this violation of protocol they were
excluded from all further analyses (Figure 2). The baseline
characteristics of the remaining 359 patients are shown inTable 1. Generally, patients receiving low dose [90Y-
DOTA]-TOC treatment in group 1 had the highest fre-
quency of characteristics for advanced disease compared
to patients recruited in succeeding groups, e.g. multiple
metastases (95.0% vs. 85.7% and 87.4%) or bone metasta-
ses (26.7% vs. 22.1% and 21.2%, Table 1).
Group 1: Low Dose [90Y-DOTA]-TOC Treatment
A total of 60 patients were treated with 200 cycles accord-
ing to the low dose protocol. The median activity per cycle
was 2.4 GBq (range: 0.9-7.8 GBq), the median cumulative
activity was 9.6 GBq (range: 1.7-34.6 GBq; Figure 3).
Hematotoxicities developed in 39 patients (65.0%, Table 2):
leukopenia grade 1–3 developed in 13 (21.7%), anemia
grade 1–2 in 33 (55.0%) and thrombocytopenia grade 1–3
in 13 (21.7%) patients. Stabilization or decrease in tumor
size was found in 11 (18.3%), clinical improvement in 7
(11.7%) and tumor marker decrease in 5 (8.3%) patients. A
total of 17 patients (28.3%) received 28 further cycles
according to the intermediate dose protocol (median cycle
number: 4; range: 1–8). During a median follow-up of 15
(range: 1–158) months 1 patient (1.7%) developed grade 4
renal toxicity and 4 patients (6.7%) developed grade 5
renal toxicity. No grade 4 hematotoxicities were recorded
and the subsequent patients were enrolled for the inter-
mediate dose group.
Group 2: Intermediate Dose [90Y-DOTA]-TOC Treatment
A total of 77 patients were treated with 260 cycles according
to the intermediate dose protocol. The median activity per
cycle was 3.3 GBq (range: 2.0-7.4 GBq), the median cumula-
tive activity was 12.6 GBq (range: 2.4-58.5 GBq; Figure 3).
Hematotoxicities developed in 50 patients (64.9%, Table 2):
leukopenia grade 1–3 developed in 18 (23.4%), anemia grade
1–2 in 43 (55.8%) and thrombocytopenia grade 1–3 in 23
(29.9%) patients. One patient developed acute myeloic
leukemia after 4 cycles. Stabilization or decrease in tumor
size was found in 21 (27.3%), clinical improvement in 13
(16.9%) and tumor marker decrease in 13 (16.9%) patients.
A total of 20 patients (26.0%) received 31 further cycles
according to the high dose protocol (median cycle number:
4; range: 1–10). During a median of 23 months (range: 1–
118 months) of follow-up, 2 patients (2.6%) developed grade
4 renal toxicity and 3 patients (3.9%) developed grade 5
renal toxicity. No grade 4 hematotoxicities were recorded
and the subsequent patients were enrolled for the high
dose protocol.
Group 3: High Dose [90Y-DOTA]-TOC Treatment
A total of 222 patients were treated with 408 cycles
according to the high dose protocol. The median activ-
ity per cycle was 6.7 GBq (range: 3.7-8.1 GBq), the me-
dian cumulative activity was 13.3 GBq (range: 5.7-
62.2 GBq; Figure 3). Hematotoxicities developed in 166
Figure 2 Patient flow.
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oped in 77 (23.4%), anemia grade 1–3 in 145 (65.3%)
and thrombocytopenia grade 1–4 in 92 (41.4%) patients.
Stabilization or decrease in tumor size was found in 83
(37.4%), clinical improvement in 28 (12.6%) and tumor
marker decrease in 29 (13.1%) patients. A total of 38
patients (17.1%) received 57 further cycles of [90Y-
DOTA]-TOC, resulting in a median number of 2 (range:
1–8) cycles [90Y-DOTA]-TOC. During a median of
21 months (range: 1–113 months) of follow-up, 24
patients (10.8%) developed grade 4 renal toxicity and
7 patients (3.2%) developed grade 5 renal toxicity.
Overall, grade 4 hematotoxicities were recorded in 6
patients (2.7%) and no further dose escalation was
performed.
Predictors of Hematotoxicity
Higher frequencies of hematological toxicities were
found at higher [90Y-DOTA]-TOC activities applied dur-
ing a cycle (Figure 4A); however, these effects were not
statistically significant for anemia (p = 0.58), leukopenia
(p = 0.12) or thrombocytopenia (p = 0.17). One patient in
the intermediate dose group developed acute myeloid
leukemia.
Predictors of Renal Toxicity
Three patients had a baseline glomerular filtration
rate below 30 mL/min/1.73 m2; the remaining 356
patients were included in the competing risk analysesto identify predictors of kidney toxicity. These ana-
lyses suggested the highest risk of kidney toxicity at
high dose [90Y-DOTA]-TOC treatment (Hazard Ratio:
3.12 (1.13-8.59) vs. intermediate dose, p = 0.027,
Figure 4B). A further predictor for kidney toxicity
was a low baseline glomerular filtration rate (Table 3).Predictors of Survival
In the low dose group (median follow-up: 15 months,
range: 1–158 months), 36 patients (60.0%) died, 22
patients (36.7%) survived and 2 patients (3.3%) were
not available for follow-up. In the intermediate dose
group (median follow-up: 15 months, range: 1–
118 months), 49 patients (63.6%) died, 26 patients
(33.8%) survived and 2 patients (2.6%) were not avail-
able for follow-up. In the high dose group (median
follow-up: 15 months, range: 1–158 months), 147 patients
(66.2%) died, 74 patients (33.3%) survived and 1 patient
(0.5%) was not available for follow-up. The overall median
survival was 39 (range: 1–158) months in the low dose
group, 34 (range: 1–118) months in the intermediate
group (HR: 1.60 (0.89-2.85) vs. low dose, p = 0.11) and 29
(range: 1–113) months in the high dose group (HR: 2.50
(1.08-5.79) vs. low dose, p = 0.03, Figure 4C, Table 3).
The hazard ratios for the main predictors did not
change significantly over the enrollment period. The
predictors for the 1-, 2- and 5-years survival are listed
in Table 4.
Table 1 Baseline characteristics (n = 359)
Characteristic Low dose (n = 60) Intermediate dose (n = 77) High dose (n = 222)
Gender Females 27 (45.0%) 30 (50.6%) 98 (44.1%)
Males 33 (55.0%) 47 (49.4%) 124 (55.9%)
Age [y] Median 51.1 55.4 59.0
Range 18.1-77.0 21.9-80.5 20.5-81.1
Disease Duration [y] Median 1.9 1.4 1.9
Range 0.1-25.8 0.1-18.6 0.1-27.5
Pretreatment Surgery 35 (58.3%) 36 (46.8%) 125 (56.3%)
Chemotherapy 14 (23.3%) 16 (20.8%) 38 (17.1%)
Radiation 21 (35.0%) 31 (40.3%) 72 (32.4%)
Extent Single Metastasis 3 (5.0%) 11 (14.3%) 28 (12.6%)
Liver Metastases 48 (80.0%) 62 (80.5%) 189 (85.1%)
Bone Metastases 16 (26.7%) 17 (22.1%) 47 (21.2%)
Creatinine [μmol/L] Median 63 71 69
Range 22-258 26-138 33-369
Tumor Uptake Score 1 5 (8.3%) 10 (13.0%) 18 (8.1%)
Score 2 6 (10.0%) 8 (10.4%) 11 (5.0%)
Score 3 49 (81.7%) 59 (76.6%) 193 (87.0%)
Kidney Uptake Score 0 2 (3.3%) 3 (3.9%) 11 (5.0%)
Score 1 4 (6.6%) 8 (10.4%) 20 (0.2%)
Score 2 12 (20.0%) 10 (13.0%) 52 (23.4%)
Score 3 42 (70.0%) 55 (71.4%) 137 (61.7%)
Histology Carcinoid 19 (31.7%) 38 (49.4%) 106 (47.7%)
PNET 15 (25.0%) 21 (17.3%) 64 (28.8%)
Rare NET 17 (28.3%) 9 (11.7%) 26 (11.7%)
Unknown Primary 9 (15.0%) 9 (11.7%) 26 (11.7%)
PNET: pancreatic neuroendocrine tumors, NET: neuroendocrine tumors, Rare NET include: medullary thyroid cancers, neuroblastomas, phaeochromocytomas,
paragangliomas, small cell lung cancers and Merkel cell cancers.
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The results of this dose escalation study suggest increasing
hematological toxicities with increasing [90Y-DOTA]-TOC
activities. Especially the high dose protocol was associated
with a low but present risk of grade 4 hematotoxicities
and a higher risk of kidney toxicities. Remarkably, the post
hoc analyses suggested a potentially longer survival under
the low dose protocol.
Hematotoxicity is an acute toxicity that can be due to ir-
radiation from [90Y-DOTA]-TOC circulating through the
body or binding to somatostatin receptors on bone mar-
row cells [19] or due to the small fraction of free 90Y that
is administered during treatment cycles and that integrates
into the bone matrix [20]. The present study suggests
higher risk of anemia, leukopenia and thrombocytopenia
at higher administered activities of [90Y-DOTA]-TOC.
These results might represent a step towards preventing
severe hematotoxicity by tailoring the applied [90Y-
DOTA]-TOC activities, e.g. in patients with preexisting
hematological toxicities.Renal toxicity, on the other hand, is a late toxicity of [90Y-
DOTA]-TOC. It is mainly due to the glomerular filtration
and the tubular retention of the radiopeptide and its frag-
ments and usually develops several months or years after
treatment. Renal toxicity still represents the dose limiting
toxicity in somatostatin based radiopeptide therapy. Renal
toxicity rates between 0% and 24% have been reported for
treatment with the radiopeptides [90Y-DOTA]-TOC and
[177Lu-DOTA]-TOC [21-26]. These studies have used dif-
ferent inclusion criteria, especially regarding the baseline
kidney function; they have used different treatment proto-
cols, different follow-up schemes and different definitions
of renal toxicity. Intra-study comparisons are highly war-
ranted to allow for a comparison of the benefits and harms
of both radiopeptides. The present results, however, suggest
that fractionated low dose protocols might help to reduce
this main toxicity of [90Y-DOTA]-TOC.
High dose [90Y-DOTA]-TOC therapy was introduced in
our department in 1999 and had become the standard
treatment regime, as the extent of short-term hematological
Figure 3 Dosage protocol.
Marincek et al. Journal of Translational Medicine 2013, 11:17 Page 7 of 10
http://www.translational-medicine.com/content/11/1/17and renal toxicities had shown to be acceptable [14]. The
high dose protocol, in comparison to more fractionated
dosage protocols, specifically allowed for a significant
reduction of travelling efforts for patients recruited from
Europe, North America, South America, Africa and Asia.
Due to the systematic evaluation of the long-term outcome
of all patients treated with [90Y-DOTA]-TOC [13] we were
now able to also analyze the long-term outcome after the
different dosage protocols. These present results reveal that
fractionated low dose protocols might help to reduce the
toxicity and improve the survival after [90Y-DOTA]-TOC.Table 2 Hematological toxicities (n = 359)
Low Dose (n = 60) Total Grade 1
Leukopenia 13 (21.7%) 5 (8.3%)
Anemia 33 (55.0%) 24 (40%)
Thrombocytopenia 13 (21.7%) 8 (13.3%
Intermediate Dose (n = 77)
Leukopenia 18 (23.4%) 9 (11.7%
Anemia 43 (55.8%) 35 (45.5%
Thrombocytopenia 23 (29.9%) 20 (26.0%
High Dose (n = 222)
Leukopenia 77 (34.7%) 31 (14.0%
Anemia 145 (65.3%) 117 (52.7
Thrombocytopenia 92 (41.4%) 68 (30.6%
All toxicities are scored according to the NCI criteria.Strengths of the present study include the comprehen-
sive recruitment of 365 patients, the sufficiently long
follow-up to detect renal toxicities months or years after
[90Y-DOTA]-TOC treatment and the use of competing
risk models to assess the long-term toxicities of [90Y-
DOTA]-TOC.
The longer survival under the low dose protocol,
nevertheless, represents an unexpected finding. How-
ever, in the present study survival was not a primary
outcome. Furthermore, treatment allocation occurred in
a non-randomized fashion, as naturally, the clinicalGrade 2 Grade 3 Grade 4
6 (10%) 2 (3.3%) 0 (0%)
9 (15%) 0 (0%) 0 (0%)
) 3 (5.0%) 2 (3.3%) 0 (0%)
) 6 (7.8%) 3 (3.9%) 0 (0%)
) 8 (10.4%) 0 (0%) 0 (0%)
) 2 (2.6%) 1 (1.3%) 0 (0%)
) 31 (14.0%) 13 (5.9%) 2 (0.9%)
%) 22 (9.9%) 5 (2.3%) 0 (0%)
) 11 (5.0%) 6 (2.7%) 7 (3.2%)
Figure 4 Binary logistic regression plots displaying the frequency of anemia, leukopenia and thrombocytopenia at different
therapeutic [90Y-DOTA]-TOC activities (A). Cumulative incidence functions displaying the proportion of patients with renal toxicity are shown
for low-dose, intermediate dose and high-dose [90Y-DOTA]-TOC treatment (B). Covariate-adjusted Kaplan-Meier estimates of overall survival are
shown for low-dose, intermediate dose and high-dose [90Y-DOTA]-TOC treatment (C).
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dose escalation study. Dose escalation studies may princi-
pally underestimate the outcome of patients receiving the
initial dosage regime due to recruitment of very advanced
cases to initially receive a new drug or due to advances in
supportive care during the enrollment period. Still, in the
present analysis, which was adjusted for all baseline
characteristics and the cumulative administered activ-
ity, the longest survival was found for the initial dos-
age step. A randomized trial is warranted in order to
confirm the results on survival and long-term toxicity
of fractionated versus high dose [90Y-DOTA]-TOCtherapy. Such a prospective trial should use the
ECOG status [27], the ENETS grading system [28]
and RECIST criteria [29] to investigate potential dif-
ferences in response as well as differences in the
time-to-progression at different dosage schemes. Fur-
thermore, such a trial should examine a possible cor-
relation of pre-existing diabetes, hypertension and
proteinuria on kidney toxicity after [90Y-DOTA]-TOC.
In conclusion, herein we describe the outcome after clin-
ical introduction and dose escalation of [90Y-DOTA]-TOC
for somatostatin receptor targeted therapy in patients with
metastasized neuroendocrine tumors. This study compares
Table 3 Hazard ratios for overall survival and severe kidney toxicities (n = 359)
Covariate Hazard ratio (95% CI)* P Value
Overall survival
Gender (male vs. females) 0.97 (0.74-1.28) 0.84
Age (per year) 1.004 (0.99-1.02) 0.49
Duration of Disease (per year) 0.98 (0.94-1.02) 0.30
Previous Surgery (vs. no surgery) 0.62 (0.45-0.84) 0.002
Previous Systemic Therapies (vs. no systemic therapies) 1.48 (1.08-2.01) 0.014
Previous Radiation (vs. no radiation) 0.93 (0.64-1.36) 0.71
Single Metastasis (vs. multiple metastases) 0.66 (0.26-1.35) 0.26
Liver Metastases (vs. no liver metastases) 1.45 (0.86-2.44) 0.17
Bone Metastases (vs. no bone metastases) 1.57 (1.10-2.23) 0.013
Tumor Uptake Score 2 (vs. Uptake Score 1) 0.70 (0.31-1.61) 0.40
Tumor Uptake Score 3 (vs. Uptake Score 1) 0.40 (0.18-0.91) 0.028
Low Dose [90Y-DOTA]-TOC (vs. High Dose) 0.40 (0.17-0.93) 0.03
Intermediate Dose [90Y-DOTA]-TOC (vs. High Dose) 0.64 (0.38-1.06) 0.08
Severe Kidney Toxicity
Gender (male vs. females) 0.62 (0.33-1.18) 0.14
Age (per 10 years) 0.99 (0.96-1.02) 0.64
Baseline Glomerular Filtration Rate (per 10 mL/min/1.73 m2) 1.23 (1.09-1.39) 0.001
Low Dose [90Y-DOTA]-TOC (vs. High Dose) 0.54 (0.20-1.43) 0.21
Intermediate Dose [90Y-DOTA]-TOC (vs. High Dose) 0.32 (0.11-0.88) 0.027
*Estimates for each co-variable have been adjusted for histology as a categorical co-variable, for the cumulative [90Y-DOTA]-TOC activity as well as for all other
co-variables listed.
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ferent [90Y-DOTA]-TOC dosage protocols applied. In-
creasing [90Y-DOTA]-TOC activities may be associated
with increasing hematological toxicity. The dose related
hematotoxicity profile of [90Y-DOTA]-TOC could facilitateTable 4 Hazard ratios for overall survival 1, 2 and 5 years aft
1-YEAR SUR
Covariate Hazard
ratio (95% C
Gender (male vs. females) 1.00 (0.61-1.6
Age (per 10 years) 1.00 (0.98-1.0
Duration of Disease (per year) 0.94 (0.86-1.0
Previous Surgery (vs. no surgery) 0.59 (0.33-1.0
Previous Chemotherapy (vs. no chemotherapy) 1.28 (0.75-2.1
Previous Radiation (vs. no radiation) 0.63 (0.31-1.3
Solitary Metastases (vs. multiple metastases) 0.38 (0.11-1.3
Liver Metastases (vs. no liver metastases) 1.83 (0.68-4.9
Bone Metastases (v. no bone metastases) 1.59 (0.90-2.8
Tumor Uptake Score 2 (vs. uptake score 1) 1.47 (0.35-6.1
Tumor Uptake Score 3 (vs. uptake score 1) 0.51 (0.13-2.0
Low Dose [90Y-DOTA]-TOC (vs. High Dose) 0.93 (0.19-4.5
Intermediate Dose [90Y-DOTA]-TOC (vs. High Dose) 0.74 (0.24-2.3
*Estimates for each co-variable have been adjusted for histology as a categorical co
variables listed.tailoring [90Y-DOTA]-TOC in patients with preexisting
hematotoxicities. The results on the long-term outcome
suggest that fractionated [90Y-DOTA]-TOC treatment
might allow to reduce renal toxicity and to improve the
overall survival.er start of [90Y-DOTA]-TOC Therapy (n = 359)
VIVAL 2-YEARS SURVIVAL 5-YEARS SURVIVAL
I)*
P Value Hazard
ratio (95% CI)*
P Value Hazard
ratio (95% CI)*
P Value
3) 0.99 1.08 (0.75-1.57) 0.66 1.00 (0.75-1.35) 0.98
2) 0.69 0.99 (0.98-1.00) 0.19 1.00 (0.99-1.01) 0.83
4) 0.22 0.93 (0.86-0.99) 0.03 0.97 (0.93-1.01) 0.16
4) 0.07 0.57 (0.38-0.87) 0.009 0.63 (0.45-0.87) 0.006
9) 0.37 1.28 (0.86-1.93) 0.23 1.68 (1.21-2.32) 0.002
1) 0.22 0.75 (0.45-1.25) 0.27 0.93 (0.62-1.39) 0.72
7) 0.14 0.60 (0.22-1.60) 0.31 0.63 (0.29-1.38) 0.25
5) 0.24 1.40 (0.68-2.92) 0.36 1.57 (0.88-2.80) 0.13
1) 0.11 1.18 (0.74-1.87) 0.49 1.38 (0.94-2.01) 0.10
4) 0.60 2.10 (0.69-6.42) 0.19 0.77 (0.31-1.92) 0.58
9) 0.35 0.85 (0.28-2.61) 0.78 0.40 (0.16-0.98) 0.05
8) 0.93 0.39 (0.13-1.19) 0.10 0.39 (0.16-0.96) 0.04
1) 0.61 0.52 (0.25-1.11) 0.09 0.57 (0.33-0.99) 0.05
-variable, for the cumulative [90Y-DOTA]-TOC activity as well as for all other co-
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